Screener
Nuvectis Pharma, Inc. NVCT Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055318
| Line item | Three Months Ended March 31 / 2026 | Three Months Ended March 31 / 2025 |
|---|---|---|
| OPERATING EXPENSES | ||
| Research and development | $4,106 | $3,680 |
| General and administrative | 2,154 | 1,888 |
| OPERATING LOSS | (6,260) | (5,568) |
| Finance income | 210 | 236 |
| NET LOSS | $(6,050) | $(5,332) |
| TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | $(6,050) | $(5,332) |
| BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING, see Note 6 | $(0.26) | $(0.27) |
Item 1. Financial Statements
FAQ
- What is Nuvectis Pharma, Inc.'s operating income?
- Nuvectis Pharma, Inc. (NVCT) reported operating income of -$6.26M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s operating income changed year-over-year?
- Nuvectis Pharma, Inc.'s operating income decreased by 12.4% year-over-year, from -$5.57M to -$6.26M.
- What is the long-term trend for Nuvectis Pharma, Inc.'s operating income?
- Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s operating income has grown at a 20.9% compound annual growth rate (CAGR), from -$12.89M to -$27.57M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Nuvectis Pharma, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude